(3S,4R)-4-methylpyrrolidin-3-ol hydrochloride | 1821737-27-2

• 英文名称: (3S,4R)-4-methylpyrrolidin-3-ol hydrochloride
• 英文别名: (3S,4R)-4-methylpyrrolidin-3-olhydrochloride；(3S,4R)-4-methylpyrrolidin-3-ol;hydrochloride
• CAS: 1821737-27-2；265108-42-7
• 化学式: C₅H₁₁NO*ClH
• 分子量: 137.609
• InChiKey: VBEGDUJNLVSIES-TYSVMGFPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.01
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3S,4R)-4-methylpyrrolidin-3-ol hydrochloride 、 N-(3-methyl-4-((1-methyl-1H-benzo[d]imidazol-5-yl)oxy)phenyl)-6-(methylsulfonyl)pyrimido[5,4-d]pyrimidin-4-amine 在 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 2.0h， 以83%的产率得到(3S,4R)-4-methyl-1-(8-((3-methyl-4-((1-methyl-1H-benzo[d]imidazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)pyrrolidin-3-ol
  参考文献：
  名称：

  [EN] HER2 MUTATION INHIBITORS
  [FR] INHIBITEURS DE MUTATION HER2

  摘要：

  本发明涉及式(I)的化合物及其对映体，以及式(I)及其对映体的药用可接受盐，其中L1、L2、R1、R2、R3和n如本文所定义。本发明还涉及包括这些化合物和盐的药物组合物，以及利用这些化合物、盐和组合物治疗需要的受试者中的异常细胞生长，包括癌症的方法和用途。

  公开号：

  WO2022003575A1

文献信息

• PYRAZOL DERIVATIVES
  申请人：Aebi Johannes

  公开号：US20090029963A1

  公开（公告）日：2009-01-29

  The invention is concerned with novel pyrazol derivatives of formula (I), wherein R 1 , R 2 , R 3 , R 4 , X and Y are as defined herein, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor and/or CCR-5 receptor and can be used as medicaments.

  这项发明涉及式(I)的新型吡唑衍生物， 其中 R 1 ，R 2 ，R 3 ，R 4 ，X和Y如本文所定义，以及其生理上可接受的盐。这些化合物是CCR-2受体和/或CCR-5受体的拮抗剂，可用作药物。
• SUBSTITUTED PYRAZOLOPYRIMIDINES AS IRAK4 INHIBITORS
  申请人：Bayer AG

  公开号：EP3800188A1

  公开（公告）日：2021-04-07

  The present application relates to novel pyrazolopyrimidine derivatives for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases in humans and in animals, especially of proliferative disorders, autoimmune disorders, metabolic and inflammatory disorders characterized by an overreacting immune system, in particular rheumatological disorders, inflammatory skin disorders, cardiovascular disorders, lung disorders, eye disorders, neurological disorders, pain disorders and cancer, in human as well as of allergic and/or inflammatory diseases in animals, especially of atopic dermatitis and/or Flea Allergy Dermatitis, and especially in domestic animals, particularly in dogs.

  本申请涉及用于治疗和/或预防疾病的新的吡唑并嘧啶衍生物，以及将它们用于生产用于治疗和/或预防人类和动物疾病的药物，尤其是增殖性疾病、自身免疫性疾病、代谢和炎症性疾病，这些疾病的特点是免疫系统过度反应，特别是风湿性疾病、炎症性皮肤病、心血管疾病、肺部疾病、眼病、神经系统疾病、疼痛疾病和癌症，在人类中，以及动物的过敏性/或炎症性疾病，特别是异位性皮炎和/或跳蚤过敏性皮炎，尤其是在家养动物中，特别是在狗中。
• Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV)
  申请人：Janssen Sciences Ireland Unlimited Company

  公开号：US11339165B2

  公开（公告）日：2022-05-24

  The invention concerns compounds having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection. Formula (Ia).

  本发明涉及具有抗病毒活性的化合物，尤其是对呼吸道合胞病毒（RSV）的复制具有抑制活性的化合物。本发明还涉及包含这些化合物的药物组合物以及用于治疗呼吸道合胞病毒感染的化合物。式 (Ia).
• NEW PYRAZOL DERIVATIVES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2182953A2

  公开（公告）日：2010-05-12
• PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST THE RESPIRATORY SYNCYTIAL VIRUS (RSV)
  申请人：Janssen Sciences Ireland Unlimited Company

  公开号：US20200361942A1

  公开（公告）日：2020-11-19

  The invention concerns compounds having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection. Formula (Ia).